Disease-Associated Mutations Impact DNA Methyltransferase 1 Function through Dynamic Allosteric Effects and Solvent Exposure. [PDF]
Xie S +5 more
europepmc +1 more source
Integrating NMR and contact-response analysis reveals the allosteric network driving domain closure in Enzyme I. [PDF]
Singh A +5 more
europepmc +1 more source
Synthesis of novel allosteric modulators of the G-protein coupled receptor CB1
CB1 allosteric modulators provide new opportunities to specifically regulate biological responses mediated by CB1 receptor. This approach is an attempt to infer information about the mode of binding interactions and signaling efficacy produced by ...
Samala, Sushma
core
Decoding the allosteric grammar of protein kinases: A dual-stream framework integrating protein language models and energy landscape frustration analysis. [PDF]
Gatlin W +8 more
europepmc +1 more source
Mapping of dynamic allostery within p38 alpha kinase via network analyses and NMR spectroscopy. [PDF]
Roy Acharyya S +3 more
europepmc +1 more source
Explainable AI reveals the allosteric blind spot in protein-ligand binding predictions. [PDF]
Parikh V +5 more
europepmc +1 more source
Assessing clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors. [PDF]
Taylor SI.
europepmc +1 more source
Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging. [PDF]
Eck MJ, Scott DA.
europepmc +1 more source
MDL‐800‐induced SIRT6 activation decreases age‐associated osteoarthritis in mice
Objective SIRT6 is a nuclear‐localized histone deacetylase that regulates multiple pathways associated with aging. This study aimed to determine whether systemic administration of a small molecule activator of SIRT6, MDL‐800, decreases the severity of age‐associated osteoarthritis (OA) in mice.
Matheus Moreira Perez +13 more
wiley +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source

